Crude N-[(3R)-1-phenylpiperidin-3-yl]-3-(pyridin-4-yl)-1-trityl-1H-indazole-5-carboxamide (129 mg, 0.202 mmol) was stirred with TFA (0.5 ml) at room temperature for 45 minutes. Addition TFA (1 ml) was added and the reaction mixture was stirred at room temperature for 1.5 hours. Triethylsilane (100 μl, 0.626 mmol) was added and then the reaction mixture diluted with DMSO purified by mass-triggered reverse-phase HPLC to provide N-[(3R)-1-phenylpiperidin-3-yl]-3-(pyridin-4-yl)-1H-indazole-5-carboxamide.
